Lyell Immunopharma, Inc. (NASDAQ:LYEL) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of private placement Update: US$80M · US$10.77 a share · Goldman Sachs +1 Dealers: Goldman Sachs, Leerink Partners Buyers: ARCH Venture Partners; Adage Capital Management LP; Caligan Partners LP; RTW Investments Use of proceeds: Extend cash runway into 2028, beyond the expected ronde-cel BLA submission and updated LYL273 clinical data | Nov 4, 2026 |
| Private placement of common stock and/or pre-funded warrants Announced: up to US$100M · US$13.32 a share Use of proceeds: Fund two pivotal-stage clinical trials of LYL314 and working capital for other general corporate purposes | Jul 25, 2025 |